Company Overview

Immunovant, Inc is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (“batoclimab”), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Stock Quote

Immunovant Announces Plans to Study CIDP and Graves’ Disease

Sep 7, 2022 8:00 am EDT

View Event

Recent Events

IR Contacts


Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018

Investor Relations

Immunovant, Inc.
Tom Dorney, MS, MBA
Investor Relations

Transfer Agent

Continental Stock Transfer & Trust Company, LLC
1 State Street
30th Floor
New York, NY 10004
T: 212-509-4000